Inventor · disambiguated record
Etienne De Plaen
Also filed as: DE PLAEN ETIENNE
25 granted patents·1 pending application·954 citations·filing 1991–2009
97Inventor score
Top patents by PatentIndex Score
26 records- 0196US5342774ANucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1LUDWIG INST CANCER RES·Filed 1991·Granted Aug 30, 1994·232 cites·18 claims
- 0294US5405940AIsolated nonapeptides derived from MAGE genes and uses thereofLUDWIG INST CANCER RES·Filed 1992·Granted Apr 11, 1995·129 cites·9 claims
- 0390US5620886AIsolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2LUDWIG INST CANCER RES·Filed 1993·Granted Apr 15, 1997·75 cites·13 claims
- 0490US5612201AIsolated nucleic acid molecules useful in determining expression of a tumor rejection antigen precursorLUDWIG INST CANCER RES·Filed 1994·Granted Mar 18, 1997·127 cites·3 claims
- 0579US6669946B2Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of human leukocyte antigen tyrosinase derived peptides, and methods for treating said individualsLUDWIG INST CANCER RES·Filed 2001·Granted Dec 30, 2003·5 cites·1 claims
- 0679US5487974AMethod for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cellsLUDWIG INST CANCER RES·Filed 1993·Granted Jan 30, 1996·59 cites·6 claims
- 0778US6034214AIsolated nonapeptides which bind to HLA molecules and provoke lysis by cytolytic T cellsLUDWIG INST CANCER RES·Filed 1994·Granted Mar 7, 2000·40 cites·4 claims
- 0878US5462871AIsolated nucleic acid molecules which encode MAGE derived nonapeptidesLUDWIG INST CANCER RES·Filed 1993·Granted Oct 31, 1995·52 cites·16 claims
- 0975US5925729ATumor rejection antigen precursors, tumor rejection antigens and uses thereofLUDWIG INST CANCER RES·Filed 1994·Granted Jul 20, 1999·31 cites·1 claims
- 1073US5747271AMethod for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of HLA-A2/tyrosinase derived peptides, and methods for treating said individualsLUDWIG INST CANCER RES·Filed 1996·Granted May 5, 1998·39 cites·2 claims
- 1172US5695994AIsolated cytolytic T cells specific for complexes of MAGE related peptides and HLA moleculesLUDWIG INST CANCER RES·Filed 1995·Granted Dec 9, 1997·20 cites·6 claims
- 1269US6488932B1Method for treating cancer by administering MAGE-derived peptidesLUDWIG INST CANCER RES·Filed 1995·Granted Dec 3, 2002·25 cites·4 claims
- 1369US6201111B1Methods for treating subjects with disorders characterized by expression of tumor rejection antigen precursorsLUDWIG INST CANCER RES·Filed 1999·Granted Mar 13, 2001·15 cites·1 claims
- 1469US5856091AIsolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2LUDWIG INST CANCER RES·Filed 1995·Granted Jan 5, 1999·16 cites·21 claims
- 1566US5854203ATumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2LUDWIG INST CANCER RES·Filed 1995·Granted Dec 29, 1998·25 cites·2 claims
- 1660US2011159017A1Trytophan catabolism in cancer treatment and diagnosisLUDWIG INST FOR CANCER RES LTD·Filed 2009·Application pending·0 cites
- 1757US6222012B1Isolated nonapeptides presented by HLA molecules, and uses thereofLUDWIG INST CANCER RES·Filed 1995·Granted Apr 24, 2001·10 cites·7 claims
- 1857US5837476AMethods for determining disorders by assaying for a non-tyrosinase, tumor rejection antigen precursorLUDWIG INST CANCER RES·Filed 1998·Granted Nov 17, 1998·19 cites·2 claims
- 1956US8519109B2Tumour rejection antigensHUANG LAN-QING·Filed 2009·Granted Aug 27, 2013·0 cites·12 claims
- 2052US6379901B1Method for screening for cancer using binders for MAGE related peptides and complexes of the peptide and HLA moleculesLUDWIG INST CANCER RES·Filed 1995·Granted Apr 30, 2002·12 cites·2 claims
- 2152US6001975APrecursor processed to at least one tumor rejection antigen presented by HLA-A2LUDWIG INST CANCER RES·Filed 1998·Granted Dec 14, 1999·15 cites·1 claims
- 2240US7547439B1Tumor rejection antigensLUDWIG INST CANCER RES·Filed 1999·Granted Jun 16, 2009·5 cites·12 claims
- 2337US6221593B1Method for determining cancer by determining expression of MAGE-10LUDWIG INST CANCER RES·Filed 1998·Granted Apr 24, 2001·3 cites·9 claims
- 2432US7923534B1Isolated tumor rejection antigen precursor proteins MAGE-2 and MAGE-3LUDWIG INST CANCER RES·Filed 1997·Granted Apr 12, 2011·0 cites·3 claims
- 2531USRE40089ENucleic acid molecules encoding the MAGE-1 tumor rejection antigen precursorLUDWIG INST CANCER RES·Filed 1996·Granted Feb 19, 2008·0 cites·25 claims
- 2629US6284476B1Method of identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of human leukocyte antigen/tyrosinase derived peptides, and methods for treating said individualsLUDWIG INST CANCER RES·Filed 1995·Granted Sep 4, 2001·0 cites·3 claims
Join the waitlist — get patent alerts
Get an alert when Etienne De Plaen files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →